Drugs, antibodies, and cellular therapies for treatment of and prophlyaxis against COVID-19

COVID-19 living network meta-analysis



Corticosteriods probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care.

Azithromycin, hydroxychloroquine, lopinavir/ritonavir, interferon-beta, and tocilizumab may not reduce risk of death or have an effect on any other patient-important outcome.

The impact of remdesivir on mortality, mechanical ventilation, length of hospital stay, and duration of symptoms is uncertain, but it probably does not substantially increase adverse effects leading to drug discontinuation.

*Mortality data includes trials up to 14 December, 2020.

Evidence for all other outcomes includes trials identified up to 21 October 2020.

This website is dedicated to providing up-to-date information about the use of pharmaceuticals, antiviral antibodies, and blood products in treatment and prevention of SARS-Cov-2 infection (COVID-19).

The evidence presented is the joint effort of an international group of researchers, supported by McMaster University, The BMJ, and Magic Evidence Ecosystem Foundation. We also work independently of, but in collaboration with, The World Health Organization.


This work is funded by the Canadian Institutes of Health Research

grant number VR4-172738.